Literature DB >> 10741732

Rapid ("warm") autopsy study for procurement of metastatic prostate cancer.

M A Rubin1, M Putzi, N Mucci, D C Smith, K Wojno, S Korenchuk, K J Pienta.   

Abstract

In this report, we describe the distribution of metastases from 14 patients who had hormone-refractory adenocarcinoma of the prostate and agreed while alive to undergo directed autopsies after their deaths. These autopsies were undertaken specifically to document the distribution of metastases, characterize tumors phenotypically and immunohistochemically, harvest fresh and snap frozen tumor and normal control tissues suitable for molecular examination, and establish cell lines via passages through generations of severe combined immunodeficient and athymic mice. Achievement of these goals was obtained through the development of a multidisciplinary team approach. Team members included a medical oncologist, pathologists, urologists, and researchers. The autopsy and tissue procurement teams were available on a round-the-clock basis. The tissues harvested from these autopsies yielded high-quality tumor samples, as evidenced by excellent preservation seen by light microscopy, strong prostate-specific antigen immunostaining, and the successful development of xenografts. The development and expansion of this program represent a valuable resource for molecular and clinical researchers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741732

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  103 in total

Review 1.  [Necessity and usefulness of bioinformatic methods for microarray data analysis].

Authors:  H A Kestler; R Küfer
Journal:  Urologe A       Date:  2004-06       Impact factor: 0.639

2.  Endoglin suppresses human prostate cancer metastasis.

Authors:  Minalini Lakshman; Xiaoke Huang; Vijayalakshmi Ananthanarayanan; Borko Jovanovic; Yueqin Liu; Clarissa S Craft; Diana Romero; Calvin P H Vary; Raymond C Bergan
Journal:  Clin Exp Metastasis       Date:  2010-10-28       Impact factor: 5.150

3.  ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

Authors:  Rainer Kuefer; Kathleen C Day; Celina G Kleer; Michael S Sabel; Matthias D Hofer; Sooryanarayana Varambally; Christoph S Zorn; Arul M Chinnaiyan; Mark A Rubin; Mark L Day
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

4.  Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival.

Authors:  Dinesh S Rao; Teresa S Hyun; Priti D Kumar; Ikuko F Mizukami; Mark A Rubin; Peter C Lucas; Martin G Sanda; Theodora S Ross
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

5.  Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.

Authors:  Tanya Stoyanova; Mireille Riedinger; Shu Lin; Claire M Faltermeier; Bryan A Smith; Kelvin X Zhang; Catherine C Going; Andrew S Goldstein; John K Lee; Justin M Drake; Meghan A Rice; En-Chi Hsu; Behdokht Nowroozizadeh; Brandon Castor; Sandra Y Orellana; Steven M Blum; Donghui Cheng; Kenneth J Pienta; Robert E Reiter; Sharon J Pitteri; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-30       Impact factor: 11.205

6.  EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.

Authors:  Alyse M DeHaan; Natalie M Wolters; Evan T Keller; Kathleen M Woods Ignatoski
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

7.  Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis.

Authors:  Christopher L Hall; Stephanie D Daignault; Rajal B Shah; Kenneth J Pienta; Evan T Keller
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

8.  The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

Authors:  Margaretha van der Deen; Jacqueline Akech; Tao Wang; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

9.  Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.

Authors:  Simon A Williams; Yi Xu; Angelo M De Marzo; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

10.  Altruism in terminal cancer patients and rapid tissue donation program: does the theory apply?

Authors:  Gwendolyn P Quinn; Devin Murphy; Christie Pratt; Teresita Muñoz-Antonia; Lucy Guerra; Matthew B Schabath; Marino E Leon; Eric Haura
Journal:  Med Health Care Philos       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.